Skip to main content
SpringerLink
Log in

Insulinoma

  • Chapter
Neuroendocrine Tumours

  • 1668 Accesses

Abstract

Insulinomas are rare endocrine tumors developing from pancreatic beta cells. The aim of this chapter is to summarize the clinical presentation and the diagnosis of insulinomas, to address the controversies in the preoperative and intraoperative tumor localization modalities, to discuss the role of the laparoscopic approach for tumor excision, and to update regarding new treatment modalities for patients with inoperable metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Cryer PE (2009) Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia 52(1):35–37

    CAS  PubMed  Google Scholar 

  2. de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA (2011) New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 75(3):277–284

    Google Scholar 

  3. Vezzosi D, Bennet A, Fauvel J, Caron P (2007) Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol 157(1):75–83

    CAS  PubMed  Google Scholar 

  4. de Herder WW, Niederle B, Scoazec JY et al (2006) Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84(3):183–188

    PubMed  Google Scholar 

  5. Finlayson E, Clark OH (2004) Surgical treatment of insulinomas. Surg Clin North Am 84(3):775–785

    PubMed  Google Scholar 

  6. Brandi ML (1991) Multiple endocrine neoplasia type I: general features and new insights into etiology. J Endocrinol Invest 14(1):61–72

    CAS  PubMed  Google Scholar 

  7. Hennings J, Garske U, Botling J, Hellman P (2005) Malignant insulinoma in ectopic pancreatic tissue. Dig Surg 22(5):377–379

    PubMed  Google Scholar 

  8. Service FJ (1997) Insulinoma and other islet-cell tumors. Cancer Treat Res 89:335–346

    CAS  PubMed  Google Scholar 

  9. Service FJ (1995) Hypoglycemic disorders. N Engl J Med 332(17):1144–1152

    CAS  PubMed  Google Scholar 

  10. Edis AJ, McIlrath DC, Van Heerden JA et al (1976) Insulinoma–current diagnosis and surgical management. Curr Probl Surg 13(10):1–45

    CAS  PubMed  Google Scholar 

  11. Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19(5):783–798

    CAS  PubMed  Google Scholar 

  12. Placzkowski KA, Vella A, Thompson GB et al (2009) Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987–2007. J Clin Endocrinol Metab 94(4):1069–1073

    CAS  PubMed  Google Scholar 

  13. Diaz AG, Herrera J, Lopez M, Puchulu FM, Ferraina P, Bruno OD (2008) Insulinoma associated with pregnancy. Fertil Steril 90(1):199.e1–4

    Google Scholar 

  14. Christiansen E, Vestergaard H (2008) Insulinoma in a third-trimester pregnant woman combined with pre-eclampsia: a case report and review of the diagnostic strategies. Gynecol Endocrinol 24(7):417–422

    PubMed  Google Scholar 

  15. Galun E, Ben-Yehuda A, Berlatzki J, Ben-Chetrit E, Gross DJ (1986) Insulinoma complicating pregnancy: case report and review of the literature. Am J Obstet Gynecol 155(1):64–65

    CAS  PubMed  Google Scholar 

  16. Service FJ (1999) Diagnostic approach to adults with hypoglycemic disorders. Endocrinol Metab Clin North Am 28(3):519–532, vi

    CAS  PubMed  Google Scholar 

  17. Service FJ, Natt N, Thompson GB et al (1999) Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 84(5):1582–1589

    CAS  PubMed  Google Scholar 

  18. Cryer PE, Axelrod L, Grossman AB et al (2009) Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 94(3):709–728

    CAS  PubMed  Google Scholar 

  19. Schultes B, Kern W, Oltmanns K et al (2005) Differential adaptation of neurocognitive brain functions to recurrent hypoglycemia in healthy men. Psychoneuroendocrinology 30(2):149–161

    CAS  PubMed  Google Scholar 

  20. Robbins DC, Andersen L, Bowsher R et al (1996) Report of the American Diabetes Association’s Task Force on standardization of the insulin assay. Diabetes 45(2):242–256

    CAS  PubMed  Google Scholar 

  21. Marcovina S, Bowsher RR, Miller WG et al (2007) Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup. Clin Chem 53(4):711–716

    CAS  PubMed  Google Scholar 

  22. Vezzosi D, Bennet A, Fauvel J et al (2003) Insulin levels measured with an insulin-specific assay in patients with fasting hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol 149(5):413–419

    CAS  PubMed  Google Scholar 

  23. O’Brien T, O’Brien PC, Service FJ (1993) Insulin surrogates in insulinoma. J Clin Endocrinol Metab 77(2):448–451

    PubMed  Google Scholar 

  24. Basu A, Sheehan MT, Thompson GB, Service FJ (2002) Insulinoma in chronic renal failure: a case report. J Clin Endocrinol Metab 87(11):4889–4891

    CAS  PubMed  Google Scholar 

  25. Service FJ, Dale AJ, Elveback LR, Jiang NS (1976) Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 51(7):417–429

    CAS  PubMed  Google Scholar 

  26. Kar P, Price P, Sawers S, Bhattacharya S, Reznek RH, Grossman AB (2006) Insulinomas may present with normoglycemia after prolonged fasting but glucose-stimulated hypoglycemia. J Clin Endocrinol Metab 91(12):4733–4736

    CAS  PubMed  Google Scholar 

  27. Hirshberg B, Livi A, Bartlett DL et al (2000) Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 85(9):3222–3226

    CAS  PubMed  Google Scholar 

  28. Service FJ, O’Brien PC, Kao PC, Young WF Jr (1992) C-peptide suppression test: effects of gender, age, and body mass index; implications for the diagnosis of insulinoma. J Clin Endocrinol Metab 74(1):204–210

    CAS  PubMed  Google Scholar 

  29. Saddig C, Bender R, Starke AA (2002) A new classification plot for the C-peptide suppression test. JOP 3(1):16–25

    PubMed  Google Scholar 

  30. Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17(2):161–171

    CAS  PubMed  Google Scholar 

  31. Wiesli P, Schmid C, Perren A, Pfammatter T, Spinas GA, Keller U (2004) Hypoglycemia in response to glucose and glucagon in insulinoma patients with a negative prolonged fast: functional and morphological properties. J Endocrinol Invest 27(9):832–838

    CAS  PubMed  Google Scholar 

  32. Soh AW, Kek PC (2010) Insulinoma in a patient with normal results from prolonged fast and glucagon-induced hypoglycemia. Endocr Pract 16(5):838–841

    PubMed  Google Scholar 

  33. Service FJ, Natt N (2000) The prolonged fast. J Clin Endocrinol Metab 85(11):3973–3974

    CAS  PubMed  Google Scholar 

  34. Kapoor RR, James C, Hussain K (2009) Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. Nat Clin Pract Endocrinol Metab 5(2):101–112

    CAS  PubMed  Google Scholar 

  35. Raffel A, Krausch MM, Anlauf M et al (2007) Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery 141(2):179–184; discussion 85–86

    PubMed  Google Scholar 

  36. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV (2005) Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353(3):249–254

    CAS  PubMed  Google Scholar 

  37. Connor H, Scarpello JH (1979) An insulinoma presenting with reactive hypoglycaemia. Postgrad Med J 55(648):735–738

    PubMed Central  CAS  PubMed  Google Scholar 

  38. Murad MH, Coto-Yglesias F, Wang AT et al (2009) Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 94(3):741–745

    CAS  PubMed  Google Scholar 

  39. Limburg PJ, Katz H, Grant CS, Service FJ (1993) Quinine-induced hypoglycemia. Ann Intern Med 119(3):218–219

    CAS  PubMed  Google Scholar 

  40. Grunberger G, Weiner JL, Silverman R, Taylor S, Gorden P (1988) Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up. Ann Intern Med 108(2):252–257

    CAS  PubMed  Google Scholar 

  41. Sapin R (2003) Insulin assays: previously known and new analytical features. Clin Lab 49(3–4):113–121

    CAS  PubMed  Google Scholar 

  42. Neal JM, Han W (2008) Insulin immunoassays in the detection of insulin analogues in factitious hypoglycemia. Endocr Pract 14(8):1006–1010

    PubMed  Google Scholar 

  43. Hirshberg B, Skarulis MC, Pucino F, Csako G, Brennan R, Gorden P (2001) Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab 86(2):475–477

    CAS  PubMed  Google Scholar 

  44. Thompson GB, Service FJ, Andrews JC et al (2000) Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery 128(6):937–944; discussion 44–45

    CAS  PubMed  Google Scholar 

  45. Rindi G (2010) The ENETS guidelines: the new TNM classification system. Tumori 96(5):806–809

    PubMed  Google Scholar 

  46. Rindi G, Kloppel G (2004) Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 80(Suppl 1):12–15

    CAS  PubMed  Google Scholar 

  47. Danforth DN Jr, Gorden P, Brennan MF (1984) Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 96(6):1027–1037

    PubMed  Google Scholar 

  48. Service FJ, McMahon MM, O’Brien PC, Ballard DJ (1991) Functioning insulinoma–incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 66(7):711–719

    CAS  PubMed  Google Scholar 

  49. Kloppel G, Couvelard A, Perren A et al (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90(2):162–166

    PubMed  Google Scholar 

  50. Kloppel G (2007) Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21(1):15–31

    PubMed  Google Scholar 

  51. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39(6):707–712

    PubMed  Google Scholar 

  52. Boukhman MP, Karam JM, Shaver J, Siperstein AE, DeLorimier AA, Clark OH (1999) Localization of insulinomas. Arch Surg 134(8):818–822; discussion 22–23

    CAS  PubMed  Google Scholar 

  53. Guettier JM, Kam A, Chang R et al (2009) Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab 94(4):1074–1080

    PubMed Central  CAS  PubMed  Google Scholar 

  54. Rockall AG, Reznek RH (2007) Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 21(1):43–68

    CAS  PubMed  Google Scholar 

  55. Sundin A, Vullierme MP, Kaltsas G, Plockinger U (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 90(2):167–183

    CAS  PubMed  Google Scholar 

  56. Gouya H, Vignaux O, Augui J et al (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181(4):987–992

    PubMed  Google Scholar 

  57. Noone TC, Hosey J, Firat Z, Semelka RC (2005) Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 19(2):195–211

    PubMed  Google Scholar 

  58. Semelka RC, Custodio CM, Cem Balci N, Woosley JT (2000) Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 11(2):141–148

    CAS  PubMed  Google Scholar 

  59. Pamuklar E, Semelka RC (2005) MR imaging of the pancreas. Magn Reson Imaging Clin N Am 13(2):313–330

    PubMed  Google Scholar 

  60. Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB (2000) Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 214(2):483–490

    CAS  PubMed  Google Scholar 

  61. Catalano C, Pavone P, Laghi A et al (1999) Localization of pancreatic insulinomas with MR imaging at 0.5 T. Acta Radiol 40(6):644–648

    CAS  PubMed  Google Scholar 

  62. An L, Li W, Yao KC et al (2011) Assessment of contrast-enhanced ultrasonography in diagnosis and preoperative localization of insulinoma. Eur J Radiol 80(3):675–680

    PubMed  Google Scholar 

  63. Kann PH, Rothmund M, Zielke A (2005) Endoscopic ultrasound imaging of insulinomas: limitations and clinical relevance. Exp Clin Endocrinol Diabetes 113(8):471–474

    CAS  PubMed  Google Scholar 

  64. McLean AM, Fairclough PD (2005) Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab 19(2):177–193

    CAS  PubMed  Google Scholar 

  65. Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA (2001) Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025–6. Arch Surg 136(9):1020–1025

    CAS  PubMed  Google Scholar 

  66. Norton JA (1999) Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum. Ital J Gastroenterol Hepatol 31(Suppl 2):S195–S197

    PubMed  Google Scholar 

  67. Grover AC, Skarulis M, Alexander HR et al (2005) A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 138(6):1003–1008; discussion 08

    PubMed  Google Scholar 

  68. Berends FJ, Cuesta MA, Kazemier G et al (2000) Laparoscopic detection and resection of insulinomas. Surgery 128(3):386–391

    CAS  PubMed  Google Scholar 

  69. Roland CL, Lo CY, Miller BS, Holt S, Nwariaku FE (2008) Surgical approach and perioperative complications determine short-term outcomes in patients with insulinoma: results of a bi-institutional study. Ann Surg Oncol 15(12):3532–3537

    PubMed  Google Scholar 

  70. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30(5):781–793

    CAS  PubMed  Google Scholar 

  71. Vezzosi D, Bennet A, Rochaix P et al (2005) Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 152(5):757–767

    CAS  PubMed  Google Scholar 

  72. Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20(8):716–731

    CAS  PubMed  Google Scholar 

  73. Bertherat J, Tenenbaum F, Perlemoine K et al (2003) Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 88(11):5353–5360

    CAS  PubMed  Google Scholar 

  74. Orlefors H, Sundin A, Garske U et al (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90(6):3392–3400

    CAS  PubMed  Google Scholar 

  75. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B (2005) Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 19(2):311–324

    CAS  PubMed  Google Scholar 

  76. Christ E, Wild D, Forrer F et al (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94(11):4398–4405

    CAS  PubMed  Google Scholar 

  77. Jackson JE (2005) Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 19(2):229–239

    PubMed  Google Scholar 

  78. Druce MR, Muthuppalaniappan VM, O’Leary B et al (2010) Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol 162(5):971–978

    CAS  PubMed  Google Scholar 

  79. Zhao YP, Zhan HX, Zhang TP et al (2011) Surgical management of patients with insulinomas: result of 292 cases in a single institution. J Surg Oncol 103(2):169–174

    PubMed  Google Scholar 

  80. Kooby DA, Gillespie T, Bentrem D et al (2008) Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg 248(3):438–446

    PubMed  Google Scholar 

  81. Aranha GV, Shoup M (2005) Nonstandard pancreatic resections for unusual lesions. Am J Surg 189(2):223–228

    PubMed  Google Scholar 

  82. Kaczirek K, Asari R, Scheuba C, Niederle B (2005) Organic hyperinsulinism and endoscopic surgery. Wien Klin Wochenschr 117(1–2):19–25

    PubMed  Google Scholar 

  83. Fendrich V, Waldmann J, Bartsch DK, Langer P (2009) Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 6(7):419–428

    PubMed  Google Scholar 

  84. Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P (2007) Enucleation of pancreatic neoplasms. Br J Surg 94(10):1254–1259

    CAS  PubMed  Google Scholar 

  85. Hirshberg B, Libutti SK, Alexander HR et al (2002) Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg 194(6):761–764

    PubMed  Google Scholar 

  86. Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J (2008) Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol (Oxf) 68(6):912–918

    CAS  Google Scholar 

  87. Grunenwald S, Broussaud S, Vezzosi D, Bennet A, Larrue V, Caron P (2009) Well-differentiated endocrine pancreatic tumour and Wernicke’s encephalopathy. Clin Endocrinol (Oxf) 70(1):170–171

    Google Scholar 

  88. Stabile BE (1997) Islet cell tumors. Gastroenterologist 5(3):213–232

    CAS  PubMed  Google Scholar 

  89. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH (1989) Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201–995) more effective than single therapy with either drug? Neth J Med 35(1–2):86–94

    CAS  PubMed  Google Scholar 

  90. Cohen MS, Bower RH, Fidler SM, Johnsonbaugh RE, Sode J (1973) Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. Lancet 1(7793):40–41

    CAS  PubMed  Google Scholar 

  91. Brodows RG, Campbell RG (1974) Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. J Clin Endocrinol Metab 38(1):159–162

    CAS  PubMed  Google Scholar 

  92. Novotny J, Janku F, Mares P, Petruzelka L (2005) Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer 13(9):760–762

    PubMed  Google Scholar 

  93. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334(4):246–254

    CAS  PubMed  Google Scholar 

  94. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA (1989) Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 121(1):34–40

    CAS  Google Scholar 

  95. Vezzosi D, Bennet A, Courbon F, Caron P (2008) Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf) 68(6):904–911

    CAS  Google Scholar 

  96. Reubi JC, Schar JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273–282

    CAS  PubMed  Google Scholar 

  97. Eriksson B, Oberg K, Alm G et al (1986) Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 2(8519):1307–1309

    CAS  PubMed  Google Scholar 

  98. Roche A, Girish BV, de Baere T et al (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13(1):136–140

    PubMed  Google Scholar 

  99. Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26(8):985–990

    PubMed  Google Scholar 

  100. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8):519–523

    CAS  PubMed  Google Scholar 

  101. Strosberg JR, Nasir A, Hodul P, Kvols L (2008) Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2(3):113–125

    PubMed Central  PubMed  Google Scholar 

  102. Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2):268–275

    CAS  PubMed  Google Scholar 

  103. Kulke MH, Stuart K, Enzinger PC et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406

    CAS  PubMed  Google Scholar 

  104. Dimou AT, Syrigos KN, Saif MW (2010) Neuroendocrine tumors of the pancreas: what’s new. Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”. Orlando, FL, USA. January 22–24, 2010. JOP 11(2):135–138

    PubMed  Google Scholar 

  105. Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG (2010) Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 162(5):1001–1008

    CAS  PubMed  Google Scholar 

  106. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513

    CAS  PubMed  Google Scholar 

  107. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523

    PubMed Central  CAS  PubMed  Google Scholar 

  108. Bourcier ME, Sherrod A, DiGuardo M, Vinik AI (2009) Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 94(9):3157–3162

    CAS  PubMed  Google Scholar 

  109. Kulke MH, Bergsland EK, Yao JC (2009) Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360(2):195–197

    CAS  PubMed  Google Scholar 

  110. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF (2006) Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 17(8):2236–2244

    PubMed  Google Scholar 

  111. Bernard V, Lombard-Bohas C, Taquet MC et al (2013) Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol 168(5):665–674

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Tumor Unit, Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, 12000, Jerusalem, 91120, Israel

    Simona Grozinsky-Glasberg MD & David J. Gross

  2. Department of Surgery, Shaare-Zedek Medical Center, The Hebrew University-Hadassah School of Medicine, Jerusalem, Israel

    Petachia Reissman

Authors
  1. Simona Grozinsky-Glasberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petachia Reissman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simona Grozinsky-Glasberg MD .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Suayib Yalcin

  2. Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

    Kjell Öberg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Grozinsky-Glasberg, S., Reissman, P., Gross, D.J. (2015). Insulinoma. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45215-8_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45214-1

  • Online ISBN: 978-3-662-45215-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation